Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:N Engl J Med
Hauptverfasser: Connolly, Stuart J., Crowther, Mark, Eikelboom, John W., Gibson, C. Michael, Curnutte, John T., Lawrence, John H., Yue, Patrick, Bronson, Michele D., Lu, Genmin, Conley, Pamela B., Verhamme, Peter, Schmidt, Jeannot, Middeldorp, Saskia, Cohen, Alexander T., Beyer-Westendorf, Jan, Albaladejo, Pierre, Lopez-Sendon, Jose, Demchuk, Andrew M., Pallin, Daniel J., Concha, Mauricio, Goodman, Shelly, Leeds, Janet, Souza, Sonia, Siegal, Deborah M., Zotova, Elena, Meeks, Brandi, Ahmad, Sadia, Nakamya, Juliet, Milling, Truman J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6699827/
https://ncbi.nlm.nih.gov/pubmed/30730782
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1814051
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge